Patients
Planning, not panic, as BIO weighs in on US vaccination woes
At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.
R&D
Precision, speed, impact: Evolving mass spectrometry for med...
MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Digital
From pilots to impact: What it really takes to scale GenAI i...
Just a year ago, the GenAI buzz in pharma felt like the start of a gold rush. Leaders greenlit pilots. Teams spun up proof-of-concepts.
Oncology
ASCO 2025: Building a stronger future in cancer care with a ...
From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the
R&D
Looking to early-stage companies for innovation, with Juerge...
In an interview at BIO 2025, Bayer's Juergen Eckhardt discusses the importance of external innovation and why his company is prioritising early stage.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks